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Summary
International efforts to test gene function in the mouse by the
systematic knockout of each gene are creating many lines in which
embryonic development is compromised. These homozygous lethal
mutants represent a potential treasure trove for the biomedical
community. Developmental biologists could exploit them in their
studies of tissue differentiation and organogenesis; for clinical
researchers they offer a powerful resource for investigating the
origins of developmental diseases that affect newborns. Here, we
outline a new programme of research in the UK aiming to kick-
start research with embryonic lethal mouse lines. The ‘Deciphering
the Mechanisms of Developmental Disorders’ (DMDD) programme
has the ambitious goal of identifying all embryonic lethal knockout
lines made in the UK over the next 5 years, and will use a
combination of comprehensive imaging and transcriptomics to
identify abnormalities in embryo structure and development. All
data will be made freely available, enabling individual researchers
to identify lines relevant to their research. The DMDD programme
will coordinate its work with similar international efforts through
the umbrella of the International Mouse Phenotyping Consortium
[see accompanying Special Article (Adams et al., 2013)] and,
together, these programmes will provide a novel database for
embryonic development, linking gene identity with molecular
profiles and morphology phenotypes.
Knockout mice: the potential of embryonic lethal lines
A global 10-year effort by the International Knockout Mouse
Consortium (IKMC) to create targeted knockout strains for every
gene in the mouse genome (~20,000) is now well underway. This
ambitious scheme will create an unparalleled resource for
uncovering the role of individual genes in maintaining normal
physiological function in the mouse and will be invaluable for
identifying genes that might contribute to human disease (Brown
and Moore, 2012). Standardised high-throughput phenotypic
screens have been established to characterise adult mutant lines,
coordinated by the International Mouse Phenotyping Consortium
(IMPC), and these are already identifying the impact of individual
gene mutations on adult mouse growth, metabolism, physiology
and behaviour.
However, research has shown that a strikingly large proportion
(about one-third) of all targeted knockouts in the mouse result in
embryonic or perinatal (EP) death and cannot therefore be studied
using existing pipelines, except as heterozygotes. Yet these lines
could be of tremendous value to developmental biologists seeking
to identify genes that are essential for embryogenesis. If
characterised further, these lines could provide a unique window
into the genetic regulation of tissue differentiation, organ formation
and embryo morphogenesis. The insights gained from such studies
will also shed light on the origins of human developmental disorders
and could provide an important boost for research into new
diagnostic and therapeutic approaches for these debilitating, and
sometimes lethal, conditions.
Initiating work to identify and characterise knockout mutants
that result in EP death is a priority for the IMPC [see accompanying
Special Article on the April 2012 IMPC meeting on embryo
phenotyping (Adams et al., 2013)]. In the UK, a consortium of
developmental biologists and clinician scientists funded by the
Wellcome Trust has now been formed to set the wheels in motion.
‘Deciphering the Mechanisms of Developmental Disorders’
(DMDD) is a 5-year programme, commencing in the spring of 2013,
that aims to provide systematic characterisation of all EP lethal
mouse lines generated in the UK by the Wellcome Trust Sanger
Institute (WTSI). By combining comprehensive imaging with
detailed transcriptomics, the DMDD programme aims to provide
a systematic and unbiased study of EP lethals at both the anatomical
and transcriptional levels. This will yield a novel and rich public
resource that should transform our understanding of embryo
tissue differentiation and organ morphogenesis.
Careful and standardised analysis of embryos from EP lethal lines
will also enable identification of mouse null alleles that mimic
aspects of human congenital syndromes and disease. Through such
work, the DMDD programme will provide new opportunities to
identify and investigate the underlying molecular and
developmental pathways that are disrupted in human
developmental disorders. Its work will complement existing clinical
genetic programmes [such as the Deciphering Developmental
Disorders (DDD; http://www.ddduk.org) and UK10K
1MRC National Institute for Medical Research, London, NW7 1AA, UK
2Wellcome Trust Sanger Institute, Cambridge, CB10 1SA, UK
3University of Edinburgh, Edinburgh, EH4 2XU, UK
4University of Oxford, Oxford, OX3 7BN, UK
5UCL Institute of Child Health, Gower Street, London, WC1E 6BT, UK
6Babraham Institute, Cambridge, CB22 3AT, UK
7King’s College, London, SE1 1UL, UK
8MRC Harwell, Harwell Science and Innovation Campus, Oxford, OX11 0RD, UK
9Medical University of Vienna, Universitätsring 1, 1010 Vienna, Austria
*Author for correspondence (tmohun@nimr.mrc.ac.uk)
© 2013. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution
Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which
permits unrestricted non-commercial use, distribution and reproduction in any medium
provided that the original work is properly cited and all further distributions of the work or
adaptation are subject to the same Creative Commons License terms.
D
ise
as
e 
M
od
el
s &
 M
ec
ha
ni
sm
s  
    
   D
M
M
Disease Models & Mechanisms 563
EDITORIAL
[http://www.uk10k.org] projects] that are currently exploiting the
latest generation sequencing methods in efforts to identify
previously unknown disease-associated alleles.
Outline of the DMDD phenotyping pipeline
Experience gained over more than a decade of mouse transgenics
work has revealed that approximately half of all mouse gene
knockouts demonstrating recessive EP lethality complete the major
period of organogenesis (E14.5-E15.5) and reach a point when organ
arrangement resembles that of the adult. Another third of the
knockouts develop at least to the mid-gestation stage but fail to
complete organogenesis. Furthermore, existing phenotyping efforts
show that at least 60% of all EP lethals studied to date have readily
detectable structural defects in one or more organ systems. (The
true figure is likely to be significantly higher because existing studies
have rarely been systematic, nor have they used consistent or
comparable imaging methods.) Taken together, these observations
indicate that simple screening of embryo morphology provides a
remarkably efficient way to identify genes that are important in
embryo development and organogenesis.
Such a screen lies at the heart of the DMDD pipeline (Figs 1, 2)
which will use state-of-the-art imaging methods to phenotype EP
lethal embryos based on their external and internal embryo
morphology. Where possible, embryos will be analysed after
organogenesis (E14.5-E15.5). Lines presenting no homozygous
mutant embryos at E14.5 (or those in which homozygous mutants
are evidently dying or dead) will be re-assessed at mid-gestation
(E9.5-E10.5), a stage late enough to identify structural defects in
several major organ systems, including cardiovascular and neural
tissue. Data collated by The Jackson Laboratory on existing mouse
mutants (http://www.informatics.jax.org) indicates that, by
studying embryos at these two time points, the DMDD programme
can expect to capture more than three-quarters of all structural
abnormalities in the EP embryos [see table 1 of the accompanying
Special Article (Adams et al., 2013)].
Current UK plans envisage the creation of ~270 targeted, null
lines in the UK annually [approximately 160 at the WTSI and 110
at the UK Medical Research Council (MRC) Mary Lyon Centre],
which can be expected to yield ~400 EP lethal lines over the next
5 years. At least 240 of these lines will provide viable embryos, either
at mid-gestation or after organogenesis, and will therefore be
amenable to analysis. This will dramatically extend the pool of
mouse genes known to be critical for normal embryo development,
enhancing research into the genetic networks that are responsible
for tissue organisation and organogenesis. It will also provide
experimental testing of candidate developmental disease genes
suggested from clinical studies.
Of course, embryonic lethality can arise not only through direct
disruption of embryonic tissue formation or organ function; mid-
gestational lethality or stunted growth prior to later-stage death
can also result from compromised placental development. For this
reason, the DMDD programme includes a comprehensive screen
of EP lines for placental abnormalities.
Around 15% of EP mutants are expected to show peri- or post-
natal, rather than earlier embryonic, lethality, and such embryos
are likely to exhibit no obvious morphological abnormalities at
E14.5-E15.5. For a large proportion of these mutants, the gene
knockout will affect later aspects of neural development, and will
not be easily detected using simple morphological criteria.
Nonetheless, these mutations result in severe defects (for example,
in movement, breathing, cognition, vision or suckling) that render
the pups unviable. Lines falling into this category will therefore be
assayed immediately prior to birth, initially triaged by a range of
simple tests, including assessment of appearance and the response
to stimuli. Histological analysis will be used to detect late-appearing
phenotypes such as craniosynostosis, hindbrain herniation 
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Fig. 1. Flow diagram of the DMDD programme.
Embryo viability of homozygous nulls will be
assessed 2 weeks after birth (P14) to identify EP
lethal lines. Viability of EP embryos will then be
checked at 14 days of gestation (E14.5) and viable
embryos will be comprehensively imaged for
malformations. If embryos are absent (resorbed),
embryo litters will be examined after 9 or 10 days of
gestation (E9.5-E10.5) and homozygous null
embryos identified for imaging. All possible EP lines
will be used for transcriptomics analysis at early
stages of development. EP lines that appear normal
at E14.5 will be reanalysed shortly before birth
(E18.5) in order to detect neurological
abnormalities. Data that will be presented on the
DMDD web portal is indicated by pink boxes.
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(Chiari II defect) and submucous cleft palate, whereas
immunohistochemistry will identify defects in synaptogenesis and
neuronal differentiation or morphology.
Optimising the pipeline
Evidently, any screen of this scale must balance effectiveness
against cost. This is a difficult calculus because the bulk of costs
arise simply from animal husbandry, constraining the scale of any
screening. By contrast, we can expect considerable variations in
phenotypic penetrance, despite the use of a single genetic
background, with the result that some lines will require analysis of
many more null embryos than others in order to detect the
resulting abnormalities. For the DMDD programme, we have
chosen to screen three homozygous knockout embryos, together
with one wild-type littermate, for structural defects. Assuming
phenotype penetrance of 0.5, this sample size gives a 0.875
probability of finding at least one phenotypically abnormal embryo
for each EP line. In pilot studies, this approach has proved effective
in identifying a range of specific abnormalities in virtually every
line examined.
With relatively small embryo numbers and a limited amount of
time before the lines will be archived, it is essential that embryo
structure examination is as effective as possible. Furthermore, such
data must lend itself readily to computer analysis to allow the power
of digital resectioning and three-dimensional (3D) modelling to be
harnessed in the detection of abnormal phenotypes. The DMDD
programme will utilise high-resolution episcopic microscopy
(HREM) to image embryos at the highest levels of resolution
currently feasible without histological sectioning (Fig. 3). This will
maximise our ability to identify the largest range of phenotypes by
qualitative analysis (Geyer et al., 2009).
Considerable progress has also been made in recent years using
computer-based methods for automatic registration of multiple
image data sets, paving the way for quantitative comparison of
defined embryo organs and organ regions (Dorr et al., 2008;
Zamyadi et al., 2010; Zhang et al., 2010). This technique, which
has been applied to magnetic resonance imaging (MRI) and X-ray
computed tomography (μCT) data from embryos, has the potential
to complement qualitative phenotyping. In addition to being
automated rather than manual, this approach can identify
volumetric changes that are difficult to detect in 2D analysis (Spring
et al., 2007; Spring et al., 2010). Furthermore, it can assist expert
phenotyping by highlighting regions of mutant embryos that
display the greatest variance compared with reference controls.
Because the bulk of embryo imaging in the DMDD programme
will occur after organogenesis (E14.5-E15.5), we plan to image
embryos non-invasively by μCT prior to HREM analysis. By
implementing this sequential imaging pipeline, we will accumulate
a repository of image data that has the greatest utility for future
studies, while also facilitating the use of emerging automated
analysis methods.
The value of systematic transcriptomics
As a first step towards identifying the cellular processes and
molecular pathways that are disrupted by gene deletion, the
DMDD programme will complement morphological analysis by
analysing the transcriptome of knockout embryos, using RNA
sequencing (RNA-seq). By adopting a transcript counting
methodology (Anders and Huber, 2010) developed for efficient
and cost-effective high-throughput analysis, we will be able to
detect differential expression of known protein-coding genes,
non-coding RNAs (ncRNAs) and newly identified transcripts
compared with sibling controls (Airik et al., 2005; Rodriguez-Zas
et al., 2008; Tsutsumi et al., 2008). Bioinformatic analysis could
then be used to identify candidate pathways and downstream
targets that might be affected (Lu et al., 2009). Of course, gene
expression data will only reveal the genetic consequences of gene
knockout at the stage chosen for analysis and cannot, in isolation,
distinguish between the primary molecular lesion and its
dmm.biologists.org564
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Fig. 2. Overall DMDD workflow. Mouse lines identified as EP lethal will
undergo analysis in the DMDD pipeline, with all anatomical and histological
data scored for defects. Collective data for each line will be reviewed and
published in full via the web portal.
Fig. 3. Phenotyping embryos with high-resolution episcopic microscopy
(HREM). Volume-rendered 3D models from HREM data allow the visualisation
of embryo morphology at remarkably high resolution.
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downstream consequences. However, by choosing the most
appropriate early time point for transcriptomic analysis, DMDD’s
goal is to obtain the most useful pointers to guide in-depth studies
of each mutant line (Park and Choi, 2011).
The systematic accumulation of transcriptomic data linked to
phenotypic data would open many new opportunities for basic and
translational research. The accumulated data from a large number
of mutant lines and their controls will provide an unparalleled
resource for bioinformatic analysis of likely gene networks driving
normal tissue and organ development. By hierarchically combining
information across different gene knockouts, it will be possible to
begin constructing and refining gene regulatory networks (GRNs)
that can inform our understanding of complex phenotypes (Aijö
and Lähdesmäki, 2009). In addition, this resource will be invaluable
for elucidating possible mechanisms underlying gene-based
developmental abnormalities.
Focusing on developmental disease
A key goal of DMDD is to exploit mouse studies to advance
understanding of human congenital diseases. High-throughput
sequencing studies are already transforming our knowledge of the
aetiology of such diseases, and have pinpointed homozygous and
heterozygous loss-of-function mutations as a major cause of
childhood developmental disorders. Over 300 haploinsufficient
genes have so far been identified (Huang et al., 2010; Zhang et
al., 2009), and establishing the full extent to which loss-of-
function among the 22,000 human genes causes developmental
disorders is a pressing challenge. A major obstacle is the
observation that every patient genome in fact harbours many loss-
of-function mutations; thus, distinguishing pathogenic from
benign loss-of-function variants is not easy with clinical studies
alone (Huang et al., 2010; MacArthur et al., 2012). Here, the
DMDD programme could be invaluable, by producing the
appropriate mouse lines to study loss-of-function in both
heterozygote and homozygote animals. These could be used to
directly test the putative association between loss-of-function
variants and developmental disease phenotypes in vivo.
To help achieve this goal, the DMDD programme will prioritise
the analysis of mutants for mouse genes that are orthologous to
high-confidence causal alleles associated with human
developmental disorders. Not only will this provide an experimental
test of such linkage, the associated systematic phenotyping could
unveil other associated phenotypes that merit further investigation
in a clinical context. The UK10K and DDD projects have also shown
the predictive value of gene-gene and protein-protein interaction
networks for identifying additional disease alleles. DMDD will
therefore also prioritise genes that, on the basis of network analysis,
are predicted to interact or cooperate with genes known to cause
developmental disease.
Challenges and outlook
The potential of EP lethal lines for advancing our understanding
of embryo development and the genetics of developmental disease
is easy to grasp; but the sheer scale of the opportunity afforded
by a knockout screen covering the entire mouse genome is
potentially daunting. The burden of mouse husbandry costs
enforces the need for strict selection of lines by individual
researchers, generally based on pre-existing genetic or phenotypic
data, yet this is entirely absent for many of the genes now being
identified in EP lethal lines. The DMDD programme is designed
to fill this gap, providing the molecular and structural phenotype
data to enable researchers to identify mutant lines that are
relevant to their research interests. To encourage such
engagement, all data obtained by the DMDD programme will
therefore be made freely and immediately available for review and
analysis by the research community.
Achieving this will be a considerable challenge. However, pilot
studies have demonstrated that, despite the enormous size of
individual embryo image sets, it is perfectly possible to make these
data freely accessible, using a web-based platform that can provide
real-time access to image data and its associated annotations
(http://embryoimaging.org). Systematic, qualitative phenotyping by
dedicated, expert anatomists has also proved feasible in pilot
screens. By employing a standardised ontology, phenotypers will
be able to record over 200 different abnormalities in embryo
structure that will be incorporated in searchable form into web
interface. Combined with links to the associated transcriptomics
data, the DMDD web resource will provide an unparalleled level
of phenotypic description, all of which can be reviewed and re-
assessed by individual researchers.
The consortium of scientists brought together in the DMDD
programme are drawn from across the UK and its leading research
centres, bringing together a unique combination of developmental
biology, genetics and clinical expertise. We hope that our efforts
will herald a new level of cooperation and engagement that can
help transform our understanding of embryo development and
developmental disease.
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